The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 10, 2015, Pages 1746-1753

  Urbano Ispizua, Alvaro ^a   Pavletic, Steven Z ^b   Flowers, Mary E ^c   Klein, John P ^d   Zhang, Mei Jie ^d   Carreras, Jeanette ^d   Montoto, Silvia ^e   Perales, Miguel Angel ^f   Aljurf, Mahmoud D ^g   Akpek, Görgün ^h   Bredeson, Christopher N ⁱ   Costa, Luciano J ^j   Dandoy, Christopher ^k   Freytes, César O ^l   Fung, Henry C ^m   Gale, Robert Peter ⁿ   Gibson, John ^o   Hamadani, Mehdi ^d   Hayashi, Robert J ^p   Inamoto, Yoshihiro ^c   Inwards, David J ^q   Lazarus, Hillard M ^r   Maloney, David G ^c   Martino, Rodrigo ^s   Munker, Reinhold ^t   Nishihori, Taiga ^u   Olsson, Richard F ^v,w   Rizzieri, David A ^x   Reshef, Ran ^y   Saad, Ayman ^j   Savani, Bipin N ^z   Schouten, Harry C ^aa   Smith, Sonali M ^ab   Socié, Gérard ^ac   Wirk, Baldeep ^ad   Yu, Lolie C ^ae   Saber, Wael ^d   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b NATIONAL CANCER INSTITUTE   (United States)

^c USA   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^h Banner MD Anderson Cancer Center   (United States)

ⁱ OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^j Heerskink School of Medicine   (United States)

^k CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^l UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^m FOX CHASE CANCER CENTER   (United States)

ⁿ IMPERIAL COLLEGE LONDON   (United Kingdom)

^o ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^p WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q MAYO CLINIC   (United States)

^r UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^s HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^t LOUISIANA STATE UNIVERSITY   (United States)

^u H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^v KAROLINSKA INSTITUTE   (Sweden)

^w UPPSALA UNIVERSITY   (Sweden)

^x DUKE UNIVERSITY   (United States)

^y HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^z VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^aa MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^ab UNIVERSITY OF CHICAGO   (United States)

^ac SAINT LOUIS HOSPITAL   (France)

^ad STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^ae LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

more..

Author keywords

Graft versus host disease; Lymphoma

Indexed keywords

CYCLOSPORIN; TACROLIMUS; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CHRONIC GRAFT VERSUS HOST DISEASE; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; SIBLING; ADOLESCENT; COMPARATIVE STUDY; COMPLICATION; DISEASE FREE SURVIVAL; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LYMPHOMA; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RITUXIMAB; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941315276     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.05.010     Document Type: Article

References (27)

1. Chakraverty R., Mackinnon S. Allogeneic transplantation for lymphoma. J Clin Oncol 2011, 29:1855-1863.
2. van Besien K. Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. Hematology Am Soc Hematol Educ Program 2009, 610-618.
3. Horowitz M. The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant 2008, 42(Suppl 1):S1-S2.
4. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
5. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
6. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
7. Rezvani A.R., Sandmaier B.M. Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes. Curr Opin Hematol 2013, 20:509-514.
8. van Besien K., Loberiza F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003, 102:3521-3529.
9. Peniket A.J., Ruiz de Elvira M.C., Taghipour G., et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003, 31:667-678.
10. Tam C.S., Bassett R., Ledesma C., et al. Mature results of the M.D. Anderson Cancer Center risk adapted transplantation strategy in mantle cell lymphoma. Blood 2009, 113:4144-4152.
11. Pérez-Simón J.A., Kottaridis P.D., Martino R., et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002, 100:3121-3127.
12. Cook G., Smith G.M., Kirkland K., et al. Outcome following reduced-intensity allogeneic stem cell transplantation for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2010, 16:1419-1427.
13. Boyadzis M., Arora M., Klein J.P., et al. Impact of chronic graft versus host disease on late relapse and survival after myeloablative allotransplantation for leukemia. Clin Cancer Res 2015, 21:2020-2028.
14. Baron F., Labopin M., Niederwieser D., et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Leukemia 2012, 26:2462-2468.
15. Bierman P.J., Loberiza F.R., Taghipour G., et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation-The Lymphoma Working Committee of the IBMTR and the EBMT. J Clin Oncol 2003, 21:3744-3753.
16. Lazarus H.M., Zhang M.-J., Carreras J., et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B-cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 2010, 16:35-45.
17. van Kampen R.J., Canals C., Schouten H.C., et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011, 29:1342-1348.
18. Hamadani M., Saber W., Ahn K.W., et al. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B-cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant 2013, 19:746-753.
19. Milpied N., Fielding A.K., Pearce R.M., et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996, 14:1291-1296.
20. Robinson S.P., Sureda A., Canals C., et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009, 94:230-238.
21. Bloor A.J., Thomson K., Chowdhry N., et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:50-58.
22. Thomson K.J., Morris E.C., Milligan D., et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010, 28:3695-3700.
23. Russell N.H., Byrne J.L., Faulkner R.D., et al. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005, 36:437-441.
24. Karl S., Peggs K.S., Kayani I., et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011, 29:971-978.
25. Dodero A., Spina F., Narni F., et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012, 26:520-526.
26. Storb R., Gyurkocza B., Barry E., et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013, 31:1530-1538.
27. Porter D.L., Levine B.L., Kalos M., et al. Chimeric antigen receptor-modified T-cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.